In addition, the NICE guidelines state that only for women with BRCA1 mutations, the opposing effects of potentially increased risk of breast cancer versus lifetime protection against ovarian cancer by taking OC should be discussed [20]. The gene discussed is BRCA1; the disease is breast carcinoma.